In addition, PIM-1 is essential in activating the NF-κB pathway, which allows for the survival of prostate cancer cells treated with docetaxel, whereas PIM-1 knockdown or expression of a dominant negative protein sensitizes cells to the cytotoxic effects of docetaxel [30]. The gene discussed is PIM1; the disease is prostate carcinoma.